drugset / Trial / NCT02976701
Effect of DLBS1033 After Primary PCI in Patients With STE-ACS
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a prospective, randomized, double-blind, double-dummy, and controlled clinical study over a total of 4-week therapy with DLBS1033 in the management of STE-ACS after a primary PCI. There will be 40 STE-ACS subjects (20 subjects in each group) planned to complete the study.
Timeline
- Start
- 2016-11
- Primary completion
- 2023-01
- Completion
- 2023-03
Outcome
Outcome not reported
Stopped: “The investigational cases were no longer relevant considering the recent implementation of our current national healthcare system.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DLBS1033 | Protein / enzyme biologic | 980 mg | — |
| Background | Aspirin | Small molecule | 80 mg | — |
| Background | Clopidogrel | Small molecule | 75 mg | — |